References
- Bhat SA, Czuczman MS. Novel antibodies in the treatment of non-Hodgkin's lymphoma. Neth J Med 2009;67: 311–321.
- Kim YH, Duvic M, Obitz E, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007;109:4655–4662.
- Faguer S, Launay F, Ysebaert L, et al. Acute cutaneous T-cell lymphoma transformation during treatment with alemtuzumab. Br J Dermatol 2007;157:841–842.
- Salhany KE, Cousar JB, Greer JP, et al. Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study. Am J Pathol 1988;132:265–277.
- Vergier B, de Muret A, Beylot-Barry M, et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneous Lymphomas. Blood 2000;95:2212–2218.
- Barberio E, Thomas L, Skowron F, Balme B, Dalle S. Transformed mycosis fungoides: clinicopathological features and outcome. Br J Dermatol 2007;157:284–289.
- Prochazkova M, Chevret E, Beylot-Barry M, et al. Large cell transformation of mycosis fungoides: tetraploidization within skin tumor large cells. Cancer Genet Cytogenet 2005;163:1–6.
- Ponti R, Fierro MT, Quaglino P, et al. TCRgamma-chain gene rearrangement by PCR-based GeneScan: diagnostic accuracy improvement and clonal heterogeneity analysis in multiple cutaneous T-cell lymphoma samples. J Invest Dermatol 2008;128:1030–1038.
- Villadsen LS, Skov L, Dam TN, et al. In situ depletion of CD4+ T cells in human skin by zanolimumab. Arch Dermatol Res 2007;298:449–455.